SCHEMBL4890877

SCHEMBL4890877

COc1ccc(C2(c3cccc(Br)c3)NC(=S)N3CC(OC)CN=C32)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 8/20 0.44
RXFP1 Q9HBX9 1/20 0.35
RORC P51449 1/20 0.34
CTSD P07339 2/20 0.33
BACE2 Q9Y5Z0 1/20 0.33
CHRNA1 P02708 1/20 0.31
CHRNG P07510 1/20 0.31
CHRNB1 P11230 1/20 0.31
CHRNB2 P17787 1/20 0.31
SLC6A2 P23975 1/20 0.31
CHRNB4 P30926 1/20 0.31
SLC6A4 P31645 1/20 0.31
CHRNA3 P32297 1/20 0.31
CHRNA4 P43681 1/20 0.31
SLC6A3 Q01959 1/20 0.31
CHRND Q07001 1/20 0.31
KCNH2 Q12809 1/20 0.31
MAPK1 P28482 1/20 0.30
ALDH1A1 P00352 2/20 0.30
KDM4E B2RXH2 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4886726 0.89 BACE1 (0.46) BACE1RXFP1RORCCTSDBACE2
SCHEMBL4884539 0.89 BACE1 (0.44) BACE1RXFP1RORCCTSDBACE2
SCHEMBL4887710 0.86 BACE1 (0.42) BACE1RXFP1RORCCTSDBACE2
SCHEMBL4017195 0.85 BACE1 (0.41) BACE1RXFP1RORCCTSDBACE2
SCHEMBL4010184 0.85 BACE1 (0.41) BACE1RXFP1RORCCTSDMAPK1
SCHEMBL4011710 0.83 BACE1 (0.40) BACE1RXFP1RORCCTSDALDH1A1
SCHEMBL4887919 0.83 BACE1 (0.40) BACE1RXFP1RORCCTSDCHRNA1
SCHEMBL4888786 0.83 BACE1 (0.47) BACE1RXFP1RORCCTSDBACE2
SCHEMBL4883711 0.82 BACE1 (0.48) BACE1RXFP1RORCCTSDBACE2
SCHEMBL8225490 0.81 BACE1 (0.55) BACE1RXFP1RORCCTSDBACE2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007145571-A9 AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA ASTRAZENECA AB (SE) 2008-12-11 WO disclosed
WO-2007145569-A9 AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA ASTRAZENECA AB (SE) 2008-12-11 WO disclosed
US-20080214577-A1 New Compounds 320 ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-20080214577-A1 New Compounds 320 ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-20080214577-A1 New Compounds 320 ASTRAZENECA AB (SE) 2008-09-04 US disclosed
US-20080058349-A1 New Compounds 318 ASTRAZENECA AB (SE) 2008-03-06 US disclosed
US-20080058349-A1 New Compounds 318 ASTRAZENECA AB (SE) 2008-03-06 US disclosed
US-20080058349-A1 New Compounds 318 ASTRAZENECA AB (SE) 2008-03-06 US disclosed
WO-2007145571-A1 AMINO-IMIDAZOLONES AND THEIR USE AS A MEDICAMENT FOR TREATING COGNITIVE IMPAIRMENT, ALZHEIMER DISEASE, NEURODEGENERATION AND DEMENTIA ASTRAZENECA AB (SE) 2007-12-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214577-A1 New Compounds 320 PSEN1, PSEN2, MAPT BACE1 5/4885RXFP1 3907/4885RORC 3468/4885
US-20080058349-A1 New Compounds 318 PSEN2, PSEN1, MAPT BACE1 5/4885RXFP1 4044/4885RORC 3722/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.